FDA 483 - Zenflow, Inc. - June 06, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Zenflow, Inc. in South San Francisco, CA, identified significant issues related to the conduct of an investigational study. The firm failed to provide investigators with necessary information, ensure proper monitoring, and promptly inform the FDA of significant new information, specifically concerning delayed Serious Adverse Event (SAE) reporting. These findings indicate deficiencies in clinical trial oversight and regulatory reporting practices.
ID · f40d6cf0-2738-465d-923f-dc8fb72f546d